Patient experience of the transition from Xalatan to generic latanoprost

Painter, Sally; Mead, Anna

doi:10.1038/eye.2014.71

Cited by 8 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14,15 Other reported issues with generic latanoprost included failure of a bottle to last a month, difficulty opening the cap and the lack of compliance aid. 14 There is also ongoing debate about the efficacy of generic vs brand name drops.…”

Section: Discussionmentioning

confidence: 99%

Manchester iStent study: 3-year results and cost analysis

Tan

2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the safety, efficacy, and the cost of combined phacoemulsification and single iStent insertion in open angle glaucoma (OAG) at 3-years follow-up. Methods This was a prospective, uncontrolled, interventional case series. All subjects underwent single iStent implantation combined with cataract surgery by a single surgeon and were followed up over 3 years. Primary outcome measures were the reduction in intraocular pressure (IOP) and number of glaucoma drops at 1, 2, and 3 years. The costs of the procedure vs the cost of continuation of glaucoma drops were calculated and compared in patients who completed 3-years follow-up. Results Forty-one patients were included in the study and thirty-six patients completed 3-years follow-up. Mean pre-op IOP was 21.2 mm Hg on 2.1 medications. Mean IOP was reduced to 15.9 mm Hg on 0.5 drops, 16.1 mm Hg on 1.0 drops, and 17.1 mm Hg (Po0.001) on 1.3 drops (Po0.001) at 1, 2, and 3 years, respectively. The overall cost of combined cataract surgery and iStent was estimated to be £829.32 more in total than conservative management with brand name eye drops over 3 years (£7.70 per patient per year) and £14 176.9 more if generic drops were used. (£131.3 per patient per year). Conclusions Combined phaco-iStent proved to be a safe and effective way of managing patients with OAG over our 3-year follow-up period. The cost-effectiveness of the procedure may vary depending on whether brand name or generic eye drops are used.

show abstract

Section: Discussionmentioning

confidence: 99%

Manchester iStent study: 3-year results and cost analysis

Tan

2016

Eye

View full text Add to dashboard Cite

show abstract

“…A study examining patient experiences of the transition from Xalatan to generic latanoprost reported patients found drops from Xalatan bottles easier to instil, more comfortable in the eye and easier to open [35]. In 20% of patients, generic bottles failed to last for a full month.…”

Section: Adherence and Ease Of Usementioning

confidence: 99%

The Use of Generic Medications for Glaucoma

Tatham

2020

Journal of Ophthalmology

View full text Add to dashboard Cite

The use of generic medicines has grown considerably in recent years providing considerable cost savings. In England, generic items represented 11.7% of prescriptions for glaucoma and ocular hypertension in 2009, increasing to 55.2% of prescriptions in 2018. Generics can be brought to the market quickly and at low cost as manufacturers are not required to repeat animal or clinical research on active ingredients already approved for safety and efficacy. Although there is no regulatory requirement for studies comparing branded and generic eye drops, several randomised crossover studies have been performed comparing branded and generic prostaglandin analogues. While most have shown similar intraocular pressure lowering, studies are of short duration and have not evaluated visual field endpoints. Furthermore, differences in inactive ingredients, pH, viscosity, levels of particulate matter, and degradation over time have been reported. Other potential problems with generic eye drops include differences in bottle design affecting adherence, problems with supply, and the possibility that reduced revenue for innovator companies will lead to reduced investment in new drug development. This article reviews the potential advantages and disadvantages of generic antiglaucoma medications.

show abstract

“…There was a small crossover study by Gandolfi and Cimino, 2 which showed IOP-lowering effect in 13 out of 15 latanoprost nonresponders who switched to bimatoprost. There have also been small studies 3,4 and anecdotal reports 5 regarding issues with generic latanoprost bottles due to the different manufacturers. These reasons may account for the move away from generic latanoprost to bimatoprost.…”

mentioning

confidence: 99%

“…2 NO regulates photoreceptor metabolism in rods and cones primarily through activation of guanylyl cyclase, a key enzyme of phototransduction. 3 Experimental studies showed that higher doses of NO induce apoptotic cell death in photoreceptors. 4 Our electrophysiological data suggest that retinal toxicity of poppers is not restricted to central cone photoreceptors only, as suggested by previous reports, but that damage may well extend peripherally also affecting rod photoreceptors.…”

mentioning

confidence: 99%